Title: On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence.
Authors: Paredes-Ruiz, Karen Jaqueline; Chavira-Ramos, Karla; Orozco-Morales, Mario; Karasu, Cimen; Tinkov, Alexey A; Aschner, Michael; Santamaría, Abel; Colín-González, Ana Laura
Published In Neurotox Res, (2021 Dec)
Abstract: The endocannabinoid system (ECS) is composed of endogenous cannabinoids; components involved in their synthesis, transport, and degradation; and an expansive variety of cannabinoid receptors. Hypofunction or deregulation of the ECS is related to pathological conditions. Consequently, endogenous enhancement of endocannabinoid levels and/or regulation of their metabolism represent promising therapeutic approaches. Several major strategies have been suggested for the modulation of the ECS: (1) blocking endocannabinoids degradation, (2) inhibition of endocannabinoid cellular uptake, and (3) pharmacological modulation of cannabinoid receptors as potential therapeutic targets. Here, we focused in this review on degradation/reuptake inhibitors over cannabinoid receptor modulators in order to provide an updated synopsis of contemporary evidence advancing mechanisms of endocannabinoids as pharmacological tools with therapeutic properties for the treatment of several disorders. For this purpose, we revisited the available literature and reported the latest advances regarding the biomedical properties of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors in pre-clinical and clinical studies. We also highlighted anandamide and 2-arachidonoylglycerol reuptake inhibitors with promising results in pre-clinical studies using in vitro and animal models as an outlook for future research in clinical trials.
PubMed ID: 34741755
MeSH Terms: Animals; Brain/drug effects; Brain/metabolism; Endocannabinoids/antagonists & inhibitors; Endocannabinoids/metabolism*; Endocannabinoids/physiology; Humans